| | | | | 2 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 10 | | | |
| | | | | 13 | | | |
| | | | | 13 | | | |
| | | | | 13 | | | |
| | | | | 13 | | | |
| | | | | 14 | | | |
| | | | | 14 | | | |
| | | | | 14 | | | |
| | | | | 16 | | | |
| | | | | 17 | | | |
| | | | | 17 | | | |
| | | | | 17 | | | |
| | | | | 19 | | | |
| | | | | 19 | | | |
| | | | | 19 | | | |
| | | | | 20 | | | |
| | | | | 20 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 31 | | | |
| | | | | 31 | | | |
| | | | | 33 | | | |
| | | | | 35 | | | |
| | | | | 40 | | | |
| | | | | 40 | | | |
| | | | | 40 | | | |
| | | | | 40 | | | |
| | | | | 40 | | | |
| | | | | 40 | | | |
| | | | | 41 | | | |
| | | | | 41 | | | |
| | | | | 46 | | | |
| | | | | 46 | | |
| | | | | 46 | | | |
| | | | | 47 | | | |
| | | | | 50 | | | |
| | | | | 51 | | | |
| | | | | 51 | | | |
| | | | | 51 | | | |
| | | | | 51 | | | |
| | | | | 53 | | | |
| | | | | 53 | | | |
| | | | | 54 | | | |
| | | | | 54 | | | |
| | | | | A-1 | | |
| | |
Female
|
| |
Male
|
| |
Non-Binary
|
| |
Did Not
Disclose Gender |
| ||||||||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | | | | | | | |
Directors
|
| | | | 1 | | | | | | 6 | | | | | | | | | | | | | | |
Part II: Demographic Background* | | | | | | | | | | | | | | | | | | | | | | | | | |
African American
|
| | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | |
Alaskan Native or American Indian
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Asian
|
| | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | |
Hispanic or Latinx
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Native Hawaiian
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
White
|
| | | | 1 | | | | | | 4 | | | | | | 0 | | | | | | 0 | | |
Two or More Races or Ethnicities
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
LGBTQ+
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Did not Disclose Demographic Background
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Name
|
| |
Age
|
| |
Present Position with Nutex Health Inc.
|
|
Thomas T. Vo, M.D., MBA
|
| |
51
|
| |
Chief Executive Officer and Chairman of the Board
|
|
Warren Hosseinion M.D.
|
| |
52
|
| | President and Director | |
Mitchell Creem, MHA
|
| |
64
|
| | Independent Director | |
Cheryl Grenas, R.N., M.S.N
|
| |
64
|
| | Independent Director | |
Michael L. Reed, MPH
|
| |
66
|
| | Independent Director | |
Kelvin Spears, M.D.
|
| |
63
|
| | Director | |
Scott J. Saunders, MPPM
|
| |
61
|
| | Independent Director | |
Name
|
| |
Audit
Committee |
| |
Compensation
Committee |
| |
Nominating and
Corporate Governance Committee |
| |||||||||
Thomas T. Vo, M.D., MBA
|
| | | | | | | | | | | | | | | | | | |
Warren Hosseinion, M.D.
|
| | | | | | | | | | | | | | | | | | |
Mitchell Creem, MHA
|
| | | | X* | | | | | | X | | | | | | X | | |
Cheryl Grenas, R.N., M.S.N
|
| | | | | | | | | | X* | | | | | | X | | |
Michael L. Reed, MPH
|
| | | | X | | | | | | X | | | | | | X* | | |
Scott J. Saunders, MPPM
|
| | | | X | | | | | | X | | | | | | X | | |
Kelvin Spears, M.D.
|
| | | | | | | | | | | | | | | | | | |
| Additional Annual Retainer for Committee Membership: | | | | | | | |
|
Audit Committee Chairman
|
| | | $ | 20,000 | | |
|
Compensation Committee Chairman
|
| | | $ | 15,000 | | |
|
Nominating and Governance Committee Chairman
|
| | | $ | 15,000 | | |
|
John Waters, Audit Committee Chair
|
| | | $ | 148,743 | | |
|
Mitchell Creem, Compensation Committee Chair
|
| | | $ | 144,375 | | |
|
Michael Reed, Nominating and Governance Audit Committee Chair
|
| | | $ | 144,375 | | |
|
Cheryl Grenas, Director
|
| | | $ | 131,250 | | |
Name
|
| |
Fees Earned or
Paid in Cash ($) |
| |
Stock
Awards ($)(1) |
| |
Total ($)
|
| |||||||||
John Waters
|
| | | | 148,743 | | | | | | 0 | | | | | | 148,743 | | |
Mitchell Creem
|
| | | | 144,375 | | | | | | 0 | | | | | | 144,375 | | |
Michael Reed
|
| | | | 144,375 | | | | | | 0 | | | | | | 144,375 | | |
Cheryl Grenas
|
| | | | 131,250 | | | | | | 0 | | | | | | 131,250 | | |
| | |
Authorized
|
| |
Issued and
Outstanding |
| |
Reserved for
Future Issuance Pursuant to Outstanding Stock Options |
| |
Reserved for
Future Issuance Pursuant to Outstanding Warrants |
| |
Reserved for
Future Issuance Pursuant to Outstanding RSUs |
| |
Reserved for
Future Issuance Pursuant to 2023 Equity Plan |
| ||||||||||||||||||
Pre-Reverse Stock Split
|
| | | | 950,000,000 | | | | | | 745,426,859 | | | | | | 4,137,149 | | | | | | 97,780,228 | | | | | | 194,720 | | | | | | 15,824,784 | | |
Post-Reverse Stock Split 1 for 15
|
| | | | 950,000,000 | | | | | | 49,719,375 | | | | | | 275,810 | | | | | | 6,518,682 | | | | | | 12,980 | | | | | | 1,054,986 | | |
| | |
Authorized
|
| |
Issued and
Outstanding |
| |
Reserved for
Future Issuance Pursuant to Outstanding Stock Options |
| |
Reserved
for Future Issuance Pursuant to Outstanding Warrants |
| |
Reserved
for Future Issuance Pursuant to Outstanding RSUs |
| |
Reserved
for Future Issuance Pursuant to 2023 Equity Plan |
| ||||||||||||||||||
Pre-Reverse Stock Split
|
| | | | 950,000,000 | | | | | | 49,700,000 | | | | | | 275,810 | | | | | | 6,518,682 | | | | | | 12,980 | | | | | | 1,054,986 | | |
Post-Reverse Stock Split 1 for 2
|
| | | | 950,000,000 | | | | | | 24,850,000 | | | | | | 137,905 | | | | | | 3,259,341 | | | | | | 6,490 | | | | | | 527,493 | | |
Post-Reverse Stock Split 1 for 5
|
| | | | 950,000,000 | | | | | | 9,940,000 | | | | | | 55,162 | | | | | | 1,303,736 | | | | | | 2,596 | | | | | | 210,997 | | |
Post-Reverse Stock Split 1 for 10
|
| | | | 950,000,000 | | | | | | 4,970,000 | | | | | | 27,581 | | | | | | 651,868 | | | | | | 1,298 | | | | | | 105,499 | | |
Post-Reverse Stock Split 1 for 16
|
| | | | 950,000,000 | | | | | | 3,106,250 | | | | | | 17,238 | | | | | | 407,417 | | | | | | 811 | | | | | | 65,936 | | |
| | |
Year Ended December 31,
|
| |||||||||
| | |
2023
|
| |
2022
|
| ||||||
Audit Fees
|
| | | $ | 1,601,868 | | | | | $ | 1,424,460 | | |
Audit Related Fees
|
| | | | 105,060 | | | | | | 29,355 | | |
Tax Fees
|
| | | | 0 | | | | | | 0 | | |
Other Fees
|
| | | | 0 | | | | | | 0 | | |
Total
|
| | | $ | 1,706,928 | | | | | $ | 1,453,815 | | |
Name
|
| |
Age
|
| |
Position(s)
|
|
Tomas T. Vo, MD, MBA | | |
51
|
| | Chief Executive Officer and Chairman of the Board | |
Warren Hosseinion, MD | | |
52
|
| | President and Director | |
Joshua DeTillio | | |
48
|
| | Chief Operating Officers (as of September 5, 2023) | |
Jon Bates, MBA, CPA | | |
54
|
| | Chief Financial Officer | |
Pamela Montgomery, ESQ., LLM, MSN, BSN, RN | | |
67
|
| | Chief Legal Officer — Healthcare | |
Elisa Luqman, ESQ., MBA | | |
59
|
| | Chief Legal Officer — SEC | |
Michael Chang, MD | | |
53
|
| | Chief Medical Officer | |
Name of Beneficial Owner
|
| |
Amount and Nature of
Beneficial Ownership |
| |
Percent of Class
|
| ||||||
Tom Vo, Chairman and CEO(1)
|
| | | | 17,988,185 | | | | | | 36.20% | | |
Warren Hosseinion, President and Director(2)
|
| | | | 115,217 | | | | | | * | | |
Mitchell Creem, Director(3)
|
| | | | 26,258 | | | | | | * | | |
Cheryl Y. Grenas, Director(4)
|
| | | | 667 | | | | | | * | | |
Michael L. Reed, Director(5)
|
| | | | 667 | | | | | | * | | |
Scott J. Saunders, Director
|
| | | | — | | | | | | * | | |
Kelvin Spears, Director
|
| | | | 318,828 | | | | | | * | | |
Joshua DeTillio, Chief Operating Officer
|
| | | | 9,333 | | | | | | * | | |
Jon C. Bates, Chief Financial Officer(6)
|
| | | | 12,568 | | | | | | * | | |
Michael Chang, Chief Medical Officer(7)
|
| | | | 800,568 | | | | | | 1.61% | | |
Pamela Montgomery, Chief Legal Officer – Healthcare(8)
|
| | | | 4,100 | | | | | | * | | |
Elisa Luqman. Chief Legal Officer – SEC(9)
|
| | | | 45,332 | | | | | | * | | |
Executive Officers and Directors as a Group
|
| | | | 19,321,722 | | | | | | 38.52% | | |
| Thomas T. Vo | | | Chief Executive Officer (former CEO at Nutex Holdco); | |
|
Warren Hosseinion
|
| | President (former CEO at Clinigence); | |
| Michael Bowen | | | Chief Financial Officer (former CFO at Clinigence); | |
| Elisa Luqman | | |
Chief Legal Officer — SEC (former Chief Legal Officer at Clinigence); and
|
|
| Pam Montgomery | | | Chief Legal Officer — Healthcare (former Chief Legal Officer at Nutex Holdco). | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Stock
($) |
| |
Option
Awards ($) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| ||||||||||||||||||
Thomas T. Vo
|
| | | | 2023 | | | | | | 992,077 | | | | | | 0 | | | | | | 0 | | | | | | 13,634(5) | | | | | | 1,005,711 | | |
Chief Executive Officer(2)
|
| | | | 2022 | | | | | | 931,841 | | | | | | 0 | | | | | | 0 | | | | | | 6,384(5) | | | | | | 938,225 | | |
Warren Hosseinion
|
| | | | 2023 | | | | | | 710,180 | | | | | | 0 | | | | | | 0 | | | | | | 24,207(5) | | | | | | 734,387 | | |
President(3)
|
| | | | 2022 | | | | | | 686,350 | | | | | | 0 | | | | | | 1,960,228 | | | | | | 25,500(5) | | | | | | 2,672,078 | | |
Jon Bates
|
| | | | 2023 | | | | | | 361,582 | | | | | | 70,200(6) | | | | | | 0 | | | | | | 21,931(5) | | | | | | 453,713 | | |
Chief Financial Officer(4)
|
| | | | 2022 | | | | | | 150,000 | | | | | | 0 | | | | | | 0 | | | | | | 2,912(5) | | | | | | 152,912 | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options(#): Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#): Unexerciseable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Stock That Have Not Vested (#) |
| |
Market
Value of Shares or Units of Stock That Have Not Vested ($) |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested ($) |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) |
| ||||||||||||||||||||||||
Warren Hosseinion
|
| | | | 100,000 | | | | | | 0 | | | | | | 1.50 | | | | | | 1/27/2030 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
| | | | | 100,000 | | | | | | 0 | | | | | | 1.50 | | | | | | 1/28/2031 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
| | | | | 600,000 | | | | | | 0 | | | | | | 1.61 | | | | | | 5/11/2027 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
| | | | | 859,779 | | | | | | 0 | | | | | | 2.75 | | | | | | 9/9/2031 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Jon C. Bates
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 49,500 | | | | | | 8,910 | | |
Name
|
| |
Number of
Shares Acquired on Exercise (#) |
| |
Value
Realized on Exercise ($) |
| |
Number of
Shares Acquired on Vesting (#) |
| |
Value
Realized on Vesting ($)(1) |
| ||||||||||||
Jon C. Bates
|
| | | | — | | | | | | — | | | | | | 99,000 | | | | | $ | 14,850 | | |
Name
|
| |
Salary and
Other Cash Payments ($)(1) |
| |
Bonus
($)(2) |
| |
Vesting of
Stock Options ($)(3) |
| |
Vesting of
RSUs ($) |
| |
Health and
Dental Benefits ($)(4) |
| |
Total
($) |
| ||||||||||||||||||
Thomas T. Vo
|
| | | | 3,000,000 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 3,013,634 | | |
Warren Hosseinion
|
| | | | 1,500,000 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 24,207 | | | | | | 1,524,207 | | |
Jon C. Bates
|
| | | | 300,000 | | | | | | 0 | | | | | | 0 | | | | | | 8,910 | | | | | | 14,463 | | | | | | 323,373 | | |
Year | | | Summary Compensation Table Total for First PEO(1) | | | Summary Compensation Table Total for Second PEO(1) | | | Compensation Actually Paid to First PEO(1)(2) | | | Compensation Actually Paid to Second PEO(1)(2) | | | Average Summary Compensation Table Total for Non-PEO NEOs(1) | | | Average Compensation Actually Paid to Non-PEO NEOs(1)(2) | | | Value of Initial Fixed $100 Investment Based on TSR | | | Net Income (Loss) (in thousands) | | ||||||||||||||||||||||||
2023 | | | | | | | | | $ | | | | | | | | | | $ | | | | | $ | | | | | $ | | | | | $ | ( | | | | | $ | ( | | | ||||||
2022 | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | ( | | | | | $ | ( | | | ||||||
2021 | | | | $ | | | | | | | | | | $ | | | | | | | | | | $ | | | | | $ | | | | | $ | N/A | | | | | $ | (N/A) | | |
| | | 2023 | | | 2022 | | ||||||
FIRST PEO SUMMARY COMPENSATION TABLE TOTAL | | | | $ | | | | | $ | | | ||
Add (Subtract): | | | | | | | | | | | | | |
Fair value of equity awards granted during the year from the Summary Compensation Table | | | | $ | | | | | | | | ||
Fair value at year end of equity awards granted during the year | | | | | | | | | | | | ||
Change in fair value of equity awards granted in prior years that were unvested as of the end of the year | | | | | | | | | | | | ||
Change in fair value of equity awards granted in current year that vested during the year | | | | | | | | | | | | ||
Change in fair value of equity awards granted in prior years that vested during the year | | | | | | | | | | | | ||
Equity awards granted in prior years that were forfeited during the year | | | | | | | | | | | | ||
Tax Gross up(a) | | | | $ | | | | | | | | ||
COMPENSATION ACTUALLY PAID TOTAL | | | | $ | | | | | $ | | |
| | | 2023 | | | 2022 | | ||||||
NON-PEO NEOS SUMMARY COMPENSATION TABLE TOTAL | | | | $ | | | | | $ | | | | |
Add (Subtract): | | | | | | | | | | | | | |
Fair value of equity awards granted during the year from the Summary Compensation Table | | | | $ | ( | | | | | $ | ( | | |
Fair value at year end of equity awards granted during the year | | | | | | | | | | | | | |
Change in fair value of equity awards granted in prior years that were unvested as of the end of the year | | | | | | | | | | | | ||
Change in fair value of equity awards granted in current year that vested during the year | | | | | | | | | | | | ||
Change in fair value of equity awards granted in prior years that vested during the year | | | | | | | | | | | | ||
Equity awards granted in prior years that were forfeited during the year | | | | | | | | | | | | ||
Dividends or other earnings paid on equity awards during the year | | | | | | | | | | | | ||
Total Equity Award Related Adjustments | | | | $ | | | | | $ | | | ||
COMPENSATION ACTUALLY PAID TOTAL | | | | $ | | | | | $ | | | |
Plan category
|
| |
Number of
securities to be issued upon exercise of outstanding options, warrants and rights |
| |
Weighted-
average exercise price of outstanding options, warrants and rights |
| |
Number of
securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
| |||||||||
| | |
(a)
|
| |
(b)
|
| |
(c)
|
| |||||||||
Equity compensation plans approved by security holders
|
| | | | 5,147,770 | | | | | $ | 2.32 | | | | | | 1,352,240 | | |
Equity compensation plans not approved by security holders
|
| | | | | | | | | | | | | | | | | | |
Total
|
| | | | 5,147,770 | | | | | $ | 2.32 | | | | | | 1,352,240 | | |